Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.44 |
| ▸ | TNKS | O95271 | 6/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 4/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15534934 | 0.82 | P2RX7 (0.42) | P2RX7TNKSTNKS2MAPTMAPK1 | |
| SCHEMBL16952962 | 0.80 | S1PR1 (0.47) | S1PR1MAPTMAPK1CACNA1BAPBA1 | |
| SCHEMBL1906819 | 0.80 | AR (0.43) | MAPTMAPK1CACNA1BAPBA1NPSR1 | |
| SCHEMBL28215006 | 0.77 | S1PR1 (0.40) | S1PR1MAPTCACNA1BAPBA1MEN1 | |
| SCHEMBL16954452 | 0.77 | S1PR1 (0.36) | S1PR1MAPTARCNR2MEN1 | |
| Trifluoroacetic Acid SCHEMBL2581954 | 0.77 | P2RX7 (0.44) | P2RX7TNKSTNKS2MAPTMAPK1 | |
| SCHEMBL3293530 | 0.77 | P2RX7 (0.57) | P2RX7TNKSTNKS2CNR2CNR1 | |
| SCHEMBL44837 | 0.76 | IDO1 (0.57) | IDO1ARKMT2A | |
| SCHEMBL29389277 | 0.76 | IDO1 (0.57) | IDO1ARKMT2A | |
| SCHEMBL8047261 | 0.76 | AR (0.50) | P2RX7MAPTMAPK1CACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| EP-3555088-B1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| US-11078216-B2 | Bisaryl amides as NRF2 activators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-08-03 | — | — | US | disclosed |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| EP-3555088-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018109647-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018109647-A1 | BISARYL AMIDES AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-21 | — | — | WO | disclosed |
| WO-2013177349-A2 | QUINAZOLINEDIONES AS TANKYRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078216-B2 | Bisaryl amides as NRF2 activators | NFE2L2, KEAP1, NQO1 | P2RX7 2463/4885TNKS 1215/4885TNKS2 1049/4885 |
| US-20190330238-A1 | BISARYL AMIDES AS NRF2 ACTIVATORS | NFE2L2, KEAP1, NQO1 | P2RX7 2463/4885TNKS 1215/4885TNKS2 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.